Literature DB >> 19851745

[Options, limits and ethics of pharmacological neuroenhancement].

C Normann1, J Boldt, G Maio, M Berger.   

Abstract

Pharmacological neuroenhancement is an attempt to increase cognitive performance in healthy humans. Learning and memory, attention and vigilance or mood and social interaction are targeted by a modulation of brain plasticity. Firstly, an analysis of the current state of research shows that, until now, clinical trials of neuroenhancing drugs have demonstrated only limited efficacy and long-term side effects remain largely unexplored. Secondly, we argue that, from an ethical perspective, neuroenhancement differs from socially mediated methods of learning. Pharmacological neuroenhancement is based on notions of efficacy and control that threaten to undermine other important aspects of mental capacities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19851745     DOI: 10.1007/s00115-009-2858-2

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  57 in total

1.  Slippery slopes, wonder drugs, and cosmetic neurology: the neuroethics of enhancement.

Authors:  Richard H Dees
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

2.  Professor's little helper.

Authors:  Barbara Sahakian; Sharon Morein-Zamir
Journal:  Nature       Date:  2007-12-20       Impact factor: 49.962

Review 3.  Phosphodiesterase inhibitors for cognitive enhancement.

Authors:  Gregory M Rose; Allen Hopper; Michael De Vivo; Ashok Tehim
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

Review 4.  Effects of antidepressants on cognitive functions: a review.

Authors:  I Amado-Boccara; N Gougoulis; M F Poirier Littré; A Galinowski; H Lôo
Journal:  Neurosci Biobehav Rev       Date:  1995       Impact factor: 8.989

5.  The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat.

Authors:  K Rutten; C Lieben; L Smits; A Blokland
Journal:  Psychopharmacology (Berl)       Date:  2007-01-30       Impact factor: 4.530

6.  Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. II. Effects on two nights of recovery sleep.

Authors: 
Journal:  J Sleep Res       Date:  1995-12       Impact factor: 3.981

7.  Relative lack of cognitive effects of methylphenidate in elderly male volunteers.

Authors:  Danielle C Turner; Trevor W Robbins; Luke Clark; Adam R Aron; Jonathan Dowson; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2003-05-07       Impact factor: 4.530

8.  Effects of modafinil on working memory processes in humans.

Authors:  Ulrich Müller; Nikolai Steffenhagen; Ralf Regenthal; Peter Bublak
Journal:  Psychopharmacology (Berl)       Date:  2004-06-24       Impact factor: 4.530

9.  Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.

Authors:  Catherine J Harmer; Nicholas C Shelley; Philip J Cowen; Guy M Goodwin
Journal:  Am J Psychiatry       Date:  2004-07       Impact factor: 18.112

10.  [Medicine on demand?].

Authors:  G Maio
Journal:  Dtsch Med Wochenschr       Date:  2007-10       Impact factor: 0.628

View more
  2 in total

1.  Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics.

Authors:  Sebastian Sattler; Guido Mehlkop; Peter Graeff; Carsten Sauer
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-02-01

Review 2.  Pharmacological Neuroenhancement: Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics, and Future Perspectives.

Authors:  Johanna Daubner; Muhammad Imran Arshaad; Christina Henseler; Jürgen Hescheler; Dan Ehninger; Karl Broich; Oliver Rawashdeh; Anna Papazoglou; Marco Weiergräber
Journal:  Neural Plast       Date:  2021-01-13       Impact factor: 3.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.